
    
      Study OXN2502 is a pilot, exploratory, randomised, placebo-controlled, double-blind,
      single-dummy, parallel group study to assess efficacy and safety of OXN PR in addition to a
      patient's current dose of pregabalin compared to pregabalin alone in opioid-na√Øve subjects
      treated with pregabalin suffering from moderate to severe pain due to diabetic
      polyneuropathy.
    
  